Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Ruxolitinib Phosphate

These are related to the Ruxolitinib Phosphate news, in which you can learn about the latest trends in Ruxolitinib Phosphate and related information industry, to help you better understand and expand Ruxolitinib Phosphate market.
  • Drug Patent & Exclusivity Expiration Report - Week of July 14 2025

    2025-07-14

    This week, there are 6 drugs in the patent and exclusivity list. They are: - NOVARTIS PHARMACEUTICALS CORP's ENTRESTO, containing active ingredient SACUBITRIL; VALSARTAN - BIOCODEX SA's DIACOMIT, containing active ingredient STIRIPENTOL - PF PRISM CV's XALKORI, containing active ingredient CRIZOTINIB - INCYTE CORP's OPZELURA, containing active ingredient RUXOLITINIB PHOSPHATE - SERVIER PHARMACEUTICALS LLC's TIBSOVO, containing active ingredient IVOSIDENIB - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's KRINTAFEL, containing active ingredient TAFENOQUINE SUCCINATE Read More